Research
Hormonal
LY3537021 was well tolerated with infrequent gastrointestinal adverse events.
LY3537021 may be a safe option for patients with T2D.
StrongSupportsmedium confidence
LY3537021 was well tolerated with infrequent gastrointestinal adverse events.
Why this rating
Based on the phase 1 randomized controlled trial design.
Source
Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies
William C. Roell et al. · Molecular Metabolism · 2025
rctCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →